Researchers have made more advancements in multiple sclerosis in the last five years than in the previous 70 years. Knowing ...
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
Migraine may be a symptom of prodromal multiple sclerosis (MS), as the risk for migraine gradually increased closer to the ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
From 1996-2024, 82 cases of anaphylaxis associated with glatiramer acetate were reported to the FDA Adverse Event Reporting ...
A recent study shows that menopause may worsen Multiple Sclerosis symptoms and accelerate its progression due to a decline in ...
Patients should stop taking glatiramer acetate and seek immediate medical attention by going to an emergency room or calling ...
7d
The National Multiple Sclerosis Society, the leading global organization supporting and empowering people living with ...
Earlier studies indicated that COVID infection might cause MS symptoms to worsen, particularly if the symptoms coincide with those associated with long COVID. For this new study, researchers tracked ...
GlobalData on MSN6d
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis casesTeva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...
The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback